News Report · Oncology

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

June 13, 2026

Clinical Perspective

Camizestrant is intended for use in adult patients with hormone receptor-positive, HER2-negative breast cancer who have experienced disease progression following first-line endocrine therapy. The data presented to the advisory committee supports the potential for improved outcomes in this patient population, particularly in those with ESR1 mutations. As the approval process continues, clinicians will need to consider how to integrate camizestrant into existing treatment paradigms for HR+ breast cancer patients with endocrine resistance.

Dr. Meera Pillai · Oncology

The FDA Oncologic Drugs Advisory Committee (ODAC) convened on April 30, 2026, to evaluate the new drug application for camizestrant tablets, a novel oral selective estrogen receptor degrader (SERD) targeting ESR1 mutations in breast cancer patients. The committee discussed the proposed indication of camizestrant in combination with a CDK4/6 inhibitor for the treatment of hormone receptor-positive, HER2-negative breast cancer upon emergence of ESR1 mutation during first-line endocrine therapy ^[1].

Clinical Context

Breast cancer remains one of the most common malignancies among women in the United States, with hormone receptor-positive (HR+) breast cancer accounting for a significant proportion of cases. Patients with HR+ breast cancer often initially respond to endocrine therapies; however, resistance can develop, particularly through mutations such as ESR1. Current treatment options include aromatase inhibitors and selective estrogen receptor modulators, but there remains a critical need for effective therapies targeting resistant disease. Camizestrant, as a SERD, aims to address this gap by providing a novel mechanism of action for patients whose disease has progressed after standard endocrine therapy.

Key Findings

The ODAC discussed the new drug application for camizestrant, which aims to treat HR-positive, HER2-negative breast cancer patients with ESR1 mutations who have progressed on first-line endocrine therapy in combination with a CDK4/6 inhibitor ^[1].
The proposed regimen includes the use of camizestrant alongside palbociclib, ribociclib, or abemaciclib, enhancing the treatment landscape for this patient population.
The advisory committee's review highlighted the need for robust clinical data demonstrating the efficacy and safety of camizestrant in this specific context.
Enrollment and event rates from the pivotal trials were discussed, emphasizing the importance of comprehensive data in supporting the approval process for this novel therapy.
The primary endpoint of the pivotal trial was progression-free survival (PFS), with a focus on the duration of response in patients with ESR1 mutations.
Dosing information for camizestrant was also reviewed, with recommendations for administration to ensure optimal therapeutic outcomes.

Safety & Tolerability

Hyperkalemia reported with camizestrant — monitor during treatment ^[1].
Dizziness reported — exact frequency not available in public source summary ^[1].
Fatigue reported ^[1].
Nausea reported — advise patients to manage symptoms ^[1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[1].
Complete adverse event profile available in the full prescribing information for camizestrant ^[1].

Study Design

The pivotal trial supporting the application for camizestrant involved a randomized, open-label design with a focus on patients with ESR1 mutations. The study aimed to assess the efficacy of camizestrant in combination with CDK4/6 inhibitors compared to standard endocrine therapies. Key limitations include the need for further data on long-term outcomes and the specific population characteristics that may influence treatment efficacy. Pending data may clarify the role of camizestrant in broader treatment settings beyond the current indications.

FAQ

What is camizestrant approved for?

Camizestrant is being evaluated for the treatment of hormone receptor-positive, HER2-negative breast cancer in patients with ESR1 mutations who have progressed on first-line endocrine therapy in combination with a CDK4/6 inhibitor.

How does camizestrant work?

Camizestrant is a selective estrogen receptor degrader (SERD) that targets estrogen receptors in cancer cells, leading to their degradation and subsequent inhibition of tumor growth.

What is the recommended dose of camizestrant?

Full dosing guidance is available in the prescribing information for camizestrant.

What are the most common side effects of camizestrant?

Common side effects include hyperkalemia, dizziness, fatigue, and nausea. Monitoring and management of these side effects are essential during treatment.

References

FDA — April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Oncology in your inbox.

Related Drug Updates

FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement

FDA Approves Relacorilant for Platinum-Resistant Ovarian Cancer: 16 Months OS Improvement

FDA Approves Mirdametinib for Neurofibromatosis Type 1: 41% ORR in ReNeu Trial

Verified HCP Portal